Skip to main content
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1976 Aug;3(4):649–653. doi: 10.1111/j.1365-2125.1976.tb04889.x

Increased platelet aggregation in patients receiving chlorpromazine

Responses to 5-hydroxy-tryptamine, dopamine and n-dimethyl dopamine

D J Boullin, R P J Grimes
PMCID: PMC1428906  PMID: 22216508

Abstract

1 Platelet aggregation responses to 5-HT, dopamine, N-dimethyl dopamine and adenosine diphosphate were compared in normal subjects and patients treated with chlorpromazine (CPZ) for longer than 6 months.

2 We confirmed our previous finding that 5-HT induced aggregation is enhanced in CPZ treated patients.

3 Increased aggregation responses were also observed with dopamine and N-dimethyl dopamine.

4 Quantitative comparisons of aggregation rates and total changes in optical density of platelet rich plasma relative to adenosine diphosphate showed significant increases with 5-HT, dopamine and N-dimethyl dopamine.

5 Implication of dopaminergic mechanisms in the central effects of phenothiazines suggests that changes in dopamine induced aggregation responses may be useful in attempting correlations of clinical and pharmacological effects.

Full text

PDF
649

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boullin D. J., Green A. R., Price K. S. The mechanism of adenosine diphosphate induced platelet aggregation: binding to platelet receptors and inhibition of binding and aggregation by prostaglandin E 1 . J Physiol. 1972 Mar;221(2):415–426. doi: 10.1113/jphysiol.1972.sp009758. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Boullin D. J., Woods H. F., Grimes R. P., Grahame-Smith D. G. Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine. Br J Clin Pharmacol. 1975 Feb;2(1):29–35. doi: 10.1111/j.1365-2125.1975.tb00468.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Kelly P. H., Miller R. J. The interaction of neuroleptic and muscarinic agents with central dopaminergic systems. Br J Pharmacol. 1975 May;54(1):115–121. doi: 10.1111/j.1476-5381.1975.tb07417.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Miller R. J., Iversen L. L. Effect of chlorpromazine and some of its metabolites on the dopamine-sensitive adenylate cyclase of rat brain striatum. J Pharm Pharmacol. 1974 Feb;26(2):142–144. doi: 10.1111/j.2042-7158.1974.tb09243.x. [DOI] [PubMed] [Google Scholar]
  5. Robertson M. M., Reynolds H. T. Crouzon's disease (craniofacial dysostosis). A neuropsychiatric presentation. S Afr Med J. 1975 Jan 4;49(1):7–10. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES